AU625310B2 - Novel compositions of mineral elements and/or oligoelements and process for their preparation - Google Patents
Novel compositions of mineral elements and/or oligoelements and process for their preparation Download PDFInfo
- Publication number
- AU625310B2 AU625310B2 AU20464/88A AU2046488A AU625310B2 AU 625310 B2 AU625310 B2 AU 625310B2 AU 20464/88 A AU20464/88 A AU 20464/88A AU 2046488 A AU2046488 A AU 2046488A AU 625310 B2 AU625310 B2 AU 625310B2
- Authority
- AU
- Australia
- Prior art keywords
- elements
- composition
- concentrations
- ratios
- multielemental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 239000002366 mineral element Substances 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 10
- 230000008569 process Effects 0.000 title claims description 6
- 239000011701 zinc Substances 0.000 claims description 34
- 229910052701 rubidium Inorganic materials 0.000 claims description 24
- 229910052725 zinc Inorganic materials 0.000 claims description 23
- 239000011777 magnesium Substances 0.000 claims description 21
- 229910052700 potassium Inorganic materials 0.000 claims description 17
- 239000011669 selenium Substances 0.000 claims description 17
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 210000001789 adipocyte Anatomy 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 229910052711 selenium Inorganic materials 0.000 claims description 7
- 230000004060 metabolic process Effects 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims 1
- -1 pQtassium Chemical compound 0.000 claims 1
- 230000001502 supplementing effect Effects 0.000 claims 1
- 239000011573 trace mineral Substances 0.000 claims 1
- 235000013619 trace mineral Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000011575 calcium Substances 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 239000011651 chromium Substances 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 229910052748 manganese Inorganic materials 0.000 description 5
- 239000011572 manganese Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940091258 selenium supplement Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052750 molybdenum Inorganic materials 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960001471 sodium selenite Drugs 0.000 description 3
- 239000011781 sodium selenite Substances 0.000 description 3
- 235000015921 sodium selenite Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000021321 essential mineral Nutrition 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000000694 mesotherapy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910020630 Co Ni Inorganic materials 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910003110 Mg K Inorganic materials 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 101100502522 Mus musculus Fcor gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000005789 organism growth Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000000576 supplementary effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Silicon Polymers (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8711579 | 1987-08-14 | ||
| FR8711579A FR2619313B1 (fr) | 1987-08-14 | 1987-08-14 | Nouvelles compositions d'elements mineraux et/ou oligoelements et leur procede de preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2046488A AU2046488A (en) | 1989-02-16 |
| AU625310B2 true AU625310B2 (en) | 1992-07-09 |
Family
ID=9354201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU20464/88A Expired - Fee Related AU625310B2 (en) | 1987-08-14 | 1988-08-08 | Novel compositions of mineral elements and/or oligoelements and process for their preparation |
Country Status (7)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995013080A1 (en) * | 1993-11-08 | 1995-05-18 | Ashmont Holdings Limited | Application of trace elements to animals |
| HUT72422A (en) * | 1994-04-20 | 1996-04-29 | Beres Export Import Rt | Aquous concentrate and process for its preparation |
| AUPN104895A0 (en) * | 1995-02-10 | 1995-03-09 | Lai, John | Methods of and preparations for the treatment of ailments and disorders |
| EP1207840B1 (en) * | 1999-08-20 | 2004-10-13 | Howard Murad | Pharmaceutical compositions and methods for reducing the appearance of cellulite |
| EP2371372A1 (en) | 2010-04-01 | 2011-10-05 | Anrold Forbes | Methods of promoting appetite suppression using alkali metals |
| WO2016139530A2 (en) | 2015-03-04 | 2016-09-09 | Arnold Forbes | Compositions and methods for treating drug addiction |
-
1987
- 1987-08-14 FR FR8711579A patent/FR2619313B1/fr not_active Expired
- 1987-10-28 CH CH4221/87A patent/CH675684A5/fr not_active IP Right Cessation
-
1988
- 1988-08-04 AT AT88402036T patent/ATE72984T1/de not_active IP Right Cessation
- 1988-08-04 DE DE8888402036T patent/DE3868791D1/de not_active Expired - Fee Related
- 1988-08-04 ES ES198888402036T patent/ES2034321T3/es not_active Expired - Lifetime
- 1988-08-04 EP EP88402036A patent/EP0306377B1/fr not_active Expired - Lifetime
- 1988-08-08 AU AU20464/88A patent/AU625310B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2619313B1 (fr) | 1989-12-29 |
| AU2046488A (en) | 1989-02-16 |
| EP0306377A1 (fr) | 1989-03-08 |
| ES2034321T3 (es) | 1993-04-01 |
| DE3868791D1 (de) | 1992-04-09 |
| FR2619313A1 (fr) | 1989-02-17 |
| CH675684A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-10-31 |
| EP0306377B1 (fr) | 1992-03-04 |
| ATE72984T1 (de) | 1992-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alexanderson et al. | Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy | |
| Galván-Arzate et al. | Thallium toxicity | |
| Frimpter et al. | Reversible Fanconi syndrome caused by degraded tetracycline | |
| Jahnen-Dechent et al. | Magnesium basics | |
| Rasmussen et al. | Depression and magnesium deficiency | |
| Kenya et al. | Cereal based oral rehydration solutions. | |
| Lopez de Romaña et al. | Review of intervention products for use in the prevention and control of anemia | |
| Gorter et al. | Examination of the cutaneous absorption of copper after the use of copper-containing ointments | |
| AU625310B2 (en) | Novel compositions of mineral elements and/or oligoelements and process for their preparation | |
| US6433015B1 (en) | Method for reducing body weight | |
| Gill et al. | Hemoglobin Lepore trait: Globin synthesis in bone marrow and peripheral blood | |
| Ben‐Ishay et al. | Bioavailability of potassium from a slow‐release tablet | |
| Cohen et al. | Acquired methemoglobinemia and hemolytic anemia following excessive pyridium (phenazopyridine hydrochloride) ingestion | |
| Schulz et al. | Quantitative study of the absorption of iron salts in infants and children | |
| Jaffé | Methemoglobinemia in the differential diagnosis of cyanosis | |
| Fennell et al. | Electrocardiographic changes in acute arsenic poisoning | |
| de Carvalho et al. | Ticrynafen: a novel uricosuric antihypertensive natriuretic agent | |
| Pittman et al. | Acute and chronic myopathy associated with alcoholism | |
| Gorman et al. | Toxicity of thiocyanates used in treatment of hypertension | |
| Teunis et al. | Acute methemoglobinemia and hemolytic anemia due to toluidine blue | |
| BOHN | Agranulocytic angina following ingestion of dinitrophenol | |
| Madara et al. | Pathophysiology | |
| Levene | The absorption of potassium chloride--liquid vs. tablet | |
| Edwards | Mental disturbances related to metals | |
| Fell et al. | Zinc and other trace elements |